GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (LTS:0SZI) » Definitions » Price-to-Funds-From-Operations

Corbus Pharmaceuticals Holdings (LTS:0SZI) Price-to-Funds-From-Operations : (As of Apr. 27, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Corbus Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.